Novo Nordisk settles U.S. probe over diabetes drug for nearly $58.7 million

(Reuters) - Novo Nordisk will pay nearly $58.7 million to resolve claims the drugmaker's sales staff downplayed the importance of a warning about cancer risks on the label of its diabetes medication Victoza, the U.S. Justice Department said on Tuesday.